150 related articles for article (PubMed ID: 32710945)
41. Biomarkers and prognostic factors for malignant pleural mesothelioma.
Vigneri P; Martorana F; Manzella L; Stella S
Future Oncol; 2015; 11(24 Suppl):29-33. PubMed ID: 26638920
[TBL] [Abstract][Full Text] [Related]
42. Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma.
Birnie KA; Yip YY; Ng DC; Kirschner MB; Reid G; Prêle CM; Musk AW; Lee YC; Thompson PJ; Mutsaers SE; Badrian B
Mol Cancer Res; 2015 Jul; 13(7):1106-18. PubMed ID: 25824152
[TBL] [Abstract][Full Text] [Related]
43. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
Capkova L; Koubkova L; Kodet R
Neoplasma; 2014; 61(2):161-9. PubMed ID: 24471939
[TBL] [Abstract][Full Text] [Related]
44. Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.
Barash U; Lapidot M; Zohar Y; Loomis C; Moreira A; Feld S; Goparaju C; Yang H; Hammond E; Zhang G; Li JP; Ilan N; Nagler A; Pass HI; Vlodavsky I
J Natl Cancer Inst; 2018 Oct; 110(10):1102-1114. PubMed ID: 29579286
[TBL] [Abstract][Full Text] [Related]
45. HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma.
Wang Y; Jiang Z; Yan J; Ying S
Dis Markers; 2019; 2019():4183157. PubMed ID: 30891101
[TBL] [Abstract][Full Text] [Related]
46. Iron overload signature in chrysotile-induced malignant mesothelioma.
Jiang L; Akatsuka S; Nagai H; Chew SH; Ohara H; Okazaki Y; Yamashita Y; Yoshikawa Y; Yasui H; Ikuta K; Sasaki K; Kohgo Y; Hirano S; Shinohara Y; Kohyama N; Takahashi T; Toyokuni S
J Pathol; 2012 Nov; 228(3):366-77. PubMed ID: 22864872
[TBL] [Abstract][Full Text] [Related]
47. Serum and pleural fluid biomarkers for mesothelioma.
Creaney J; Robinson BW
Curr Opin Pulm Med; 2009 Jul; 15(4):366-70. PubMed ID: 19417672
[TBL] [Abstract][Full Text] [Related]
48. A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma.
Schelch K; Kirschner MB; Williams M; Cheng YY; van Zandwijk N; Grusch M; Reid G
Mol Oncol; 2018 Jan; 12(1):58-73. PubMed ID: 29094504
[TBL] [Abstract][Full Text] [Related]
49. Dose-response modeling of NLRP3 inflammasome-mediated diseases: asbestos, lung cancer, and malignant mesothelioma as examples.
Cox LA
Crit Rev Toxicol; 2019 Aug; 49(7):614-635. PubMed ID: 31905042
[TBL] [Abstract][Full Text] [Related]
50. Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment.
Creaney J; Robinson BWS
Chest; 2017 Jul; 152(1):143-149. PubMed ID: 28007619
[TBL] [Abstract][Full Text] [Related]
51. Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation.
Ferrari L; Carugno M; Mensi C; Pesatori AC
Front Oncol; 2020; 10():445. PubMed ID: 32318342
[TBL] [Abstract][Full Text] [Related]
52. Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma.
Santarelli L; Staffolani S; Strafella E; Nocchi L; Manzella N; Grossi P; Bracci M; Pignotti E; Alleva R; Borghi B; Pompili C; Sabbatini A; Rubini C; Zuccatosta L; Bichisecchi E; Valentino M; Horwood K; Comar M; Bovenzi M; Dong LF; Neuzil J; Amati M; Tomasetti M
Lung Cancer; 2015 Dec; 90(3):457-64. PubMed ID: 26431916
[TBL] [Abstract][Full Text] [Related]
53. MicroRNAs dysregulation in human malignant pleural mesothelioma.
Balatti V; Maniero S; Ferracin M; Veronese A; Negrini M; Ferrocci G; Martini F; Tognon MG
J Thorac Oncol; 2011 May; 6(5):844-51. PubMed ID: 21358347
[TBL] [Abstract][Full Text] [Related]
54. Exosomal transfer of miR-126 promotes the anti-tumour response in malignant mesothelioma: Role of miR-126 in cancer-stroma communication.
Monaco F; Gaetani S; Alessandrini F; Tagliabracci A; Bracci M; Valentino M; Neuzil J; Amati M; Bovenzi M; Tomasetti M; Santarelli L
Cancer Lett; 2019 Oct; 463():27-36. PubMed ID: 31400405
[TBL] [Abstract][Full Text] [Related]
55. Overview of the biochemical and genetic processes in malignant mesothelioma.
Assis LV; Isoldi MC
J Bras Pneumol; 2014; 40(4):429-42. PubMed ID: 25210967
[TBL] [Abstract][Full Text] [Related]
56. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
[TBL] [Abstract][Full Text] [Related]
57. Diagnosis of Mesothelioma.
Fels Elliott DR; Jones KD
Surg Pathol Clin; 2020 Mar; 13(1):73-89. PubMed ID: 32005436
[TBL] [Abstract][Full Text] [Related]
58. Overexpression of activin-A and -B in malignant mesothelioma - attenuated Smad3 signaling responses and ERK activation promote cell migration and invasive growth.
Tamminen JA; Yin M; Rönty M; Sutinen E; Pasternack A; Ritvos O; Myllärniemi M; Koli K
Exp Cell Res; 2015 Mar; 332(1):102-15. PubMed ID: 25557874
[TBL] [Abstract][Full Text] [Related]
59. Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
Chapel DB; Churg A; Santoni-Rugiu E; Tsujimura T; Hiroshima K; Husain AN
Lung Cancer; 2019 Jan; 127():69-75. PubMed ID: 30642555
[TBL] [Abstract][Full Text] [Related]
60. Nrf2-lncRNA controls cell fate by modulating p53-dependent Nrf2 activation as an miRNA sponge for Plk2 and p21
Joo MS; Shin SB; Kim EJ; Koo JH; Yim H; Kim SG
FASEB J; 2019 Jul; 33(7):7953-7969. PubMed ID: 30897343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
